GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Gallbladder and Pancreas/NLR and Acute Pancreaatitis - Front Med 2026
40

NLR and Acute Pancreaatitis - Front Med 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated February 1, 2026

Overview

The neutrophil-to-lymphocyte ratio (NLR) is a simple, cost-effective biomarker derived from routine blood tests. It measures the ratio of neutrophils (a type of white blood cell involved in inflammation) to lymphocytes (white blood cells associated with immune regulation). NLR has gained attention as a potential early predictor of severity, complications, and mortality in acute pancreatitis (AP).

Clinical Utility in Acute Pancreatitis

NLR has been systematically reviewed and analysed for its role in predicting outcomes in acute pancreatitis. It is particularly useful during the first 24–48 hours after hospital admission, a critical window for risk stratification. Key findings from the systematic review include:

  1. Prediction of Severe Disease:
  • Elevated NLR at admission is consistently associated with a higher likelihood of severe acute pancreatitis (SAP), which often requires intensive care.
  • NLR dynamics (changes over time) during day 1 and day 2 improve the ability to identify patients at risk of persistent organ failure (POF).
  1. Identification of Infectious Complications:
  • NLR has shown utility in predicting infection-related complications, such as infected pancreatic necrosis (IPN), which is a serious condition requiring timely intervention.
  1. Mortality Risk:
  • An admission NLR greater than 12 has been associated with in-hospital mortality, making it a valuable tool for identifying patients with a poor prognosis.
  1. Discriminative Performance:
  • NLR demonstrates acceptable sensitivity and specificity for early triage decisions, making it a practical option for emergency departments.
  • It remains clinically useful when combined with other scoring systems (e.g., APACHE II, BISAP) or laboratory markers (e.g., procalcitonin, CRP).

Advantages of NLR

  • Accessibility: NLR can be calculated from routine blood tests, making it readily available without additional costs or delays.
  • Reproducibility: It is a simple and reliable measurement.
  • Dynamic Monitoring: NLR can be tracked over time to assess changes in inflammatory status, which is crucial for managing acute pancreatitis.

Limitations and Considerations

  • Time-Specific Thresholds: The predictive accuracy of NLR depends on the timing of measurement (e.g., admission, 24 hours, 48 hours). Fixed thresholds may not account for dynamic changes.
  • Etiological Factors: The performance of NLR may vary based on the underlying cause of pancreatitis (e.g., biliary pancreatitis vs. hypertriglyceridemia).
  • Integration with Other Tools: While NLR is valuable, it is most effective when used alongside validated clinical scores and other biomarkers.

Recommendations

  • The use of NLR for early triage in acute pancreatitis is recommended, particularly in the first 48 hours.
  • Time-specific thresholds should be locally calibrated to optimize sensitivity and specificity.
  • Combining NLR with clinical scores and other laboratory markers (e.g., CRP, procalcitonin) can enhance decision-making accuracy.

Systematic Review Registration

The systematic review evaluating NLR in acute pancreatitis is registered with PROSPERO (CRD420251169592), ensuring transparency and methodological rigour.

Conclusion

The neutrophil-to-lymphocyte ratio (NLR) is a promising biomarker for early risk stratification in acute pancreatitis. Its ability to predict severe disease, persistent organ failure, infectious complications, and mortality makes it a valuable tool for guiding clinical decisions during the critical early phase of hospitalisation. Future studies should focus on refining thresholds, validating findings across different populations, and integrating NLR into composite predictive models.

Related Q&A

41

HTG-Induced Pancreatitis

HTG-Induced Pancreatitis: Overview and Latest Treatments What is HTG-Induced Pancreatitis? HTG-induced pancreatitis refers to acute pancreatitis caused by severe hypertriglyceridemia (HTG), which is an abnormally high level of...

42

EUS -guided Biliary Drainage in acute cholecystitis(GIE, Jan-2026)

The article discusses the efficacy and clinical durability of EUS-guided gallbladder drainage (EUS-GBD) as a treatment for acute cholecystitis in high-risk surgical patients. Acute cholecystitis, which is an...

43

SIMBA Trial - GUT Jan 2026

The SIMBA Trial, as described in the provided context, was a triple-blind, randomised, controlled, superiority trial aimed at evaluating whether simvastatin could reduce the recurrence of pancreatitis in...

44

Acute pancreatitis, DM and Gut Microbiota

Acute pancreatitis (AP) is a common inflammatory condition of the pancreas that often requires hospitalization. While the in-hospital mortality rate for AP has decreased significantly due to advancements...

45

New-Onset Diabetes and Pancreatic Cancer

New-Onset Diabetes (NOD) and its link to Pancreatic Cancer, specifically Pancreatic Ductal Adenocarcinoma (PDAC), is an emerging area of medical research. Glycemically defined new-onset diabetes (GNOD) has been...

46

High visceral adiposity and low skeletal muscle mass independently predict the development of acute cholecystitis in patients with gallstones: a retrospective cohort study

The retrospective cohort study you are referencing addresses the relationship between body composition and the risk of developing acute cholecystitis in patients with gallstones. The findings highlight that...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer